PharmiWeb.com - Global Pharma News & Resources
02-Jul-2019

Chronic Obstructive Pulmonary Disease Treatment Market to Reach Approximately USD 24.3 Bn by 2026

The Global Chronic Obstructive Pulmonary Disease Treatment Market Size is expected to reach USD 24.3 Billion by 2026 and growing CAGR around 4.9 % during the forecast period 2018 to 2026.

The Global Chronic Obstructive Pulmonary Disease Treatment Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2018 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2018 to 2026.

Request a Sample Copy of this Research Report at https://www.acumenresearchandconsulting.com/request-sample/1145

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Chronic Obstructive Pulmonary Disease Treatment Market.

Key Takeaways:

  • What is the market size in 2018 and the growth rate of the global Chronic Obstructive Pulmonary Disease Treatment Market?
  • What is the market drivers, restrains, opportunities governing the global Chronic Obstructive Pulmonary Disease Treatment Market?
  • Which is the largest and the fastest growing segments in the global Chronic Obstructive Pulmonary Disease Treatment Market?
  • Who are the key players operating in the market and their market position?
  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

Market Players:

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Chronic Obstructive Pulmonary Disease Treatment Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The major players associated with the Chronic Obstructive Pulmonary Disease Treatment Market are Orion Corporation, AstraZeneca, Mylan N.V., BoehringerIngelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1145

The Major Market Segments of GlobalChronic Obstructive Pulmonary Disease Treatment Marketare as below:

Market Segmentation

Market By Drug Class

  • Bronchodilators
  • Combination
  • Phosphodiesterase Type 4 Inhibitors
  • Mucokinetics
  • Corticosteroids
  • Others

Market By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Chronic Obstructive Pulmonary Disease Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
1.2.2.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Drug Class in 2017
1.2.2.3. Bronchodilators
1.2.2.4. Combination
1.2.2.5. Phosphodiesterase Type 4 Inhibitors
1.2.2.6. Mucokinetics
1.2.2.7. Corticosteroids
1.2.2.8. Others
1.2.3. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
1.2.3.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.3.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Distribution Channel in 2017
1.2.3.3. Online Pharmacies
1.2.3.4. Hospital Pharmacies
1.2.3.5. Retail Pharmacies
1.2.3.6. Others
1.2.4. Chronic Obstructive Pulmonary Disease Treatment Market by Geography
1.2.4.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017

CHAPTER 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DRUG CLASS

4.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Drug Class
4.2. Bronchodilators
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Combination
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phosphodiesterase Type 4 Inhibitors
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Mucokinetics
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Corticosteroids
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Others
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

5.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Distribution Channel
5.2. Online Pharmacies
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hospital Pharmacies
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Retail Pharmacies
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

6.1. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
6.3. U.S.
6.3.1. U.S. Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

7.1. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

9.1. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

10.1. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

11.1. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Orion Corporation
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. AstraZeneca
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Mylan N.V.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. BoehringerIngelheim Pharmaceuticals, Inc.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Teva Pharmaceutical Industries Ltd.
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. GlaxoSmithKline plc
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Novartis AG
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sunovion Pharmaceuticals, Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. CHIESI Farmaceutici S.p.A.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1145

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 02-Jul-2019